The glycine transporter-1 inhibitors NFPS and Org 24461: A pharmacological study

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 4, 2003, Pages 811-825

  Harsing Jr , Laszlo G ^a   Gacsalyi, Istvan ^a   Szabo, Geza ^a   Schmidt, Eva ^a   Sziray, Nora ^a   Sebban, Claude ^b   Tesolin Decros, Brigitte ^b   Matyus, Peter ^c   Egyed, Andras ^a   Spedding, Michael ^d   Levay, Gyorgy ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

^b Lab Biol Vieillissement Hop C   (France)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antipsychotic agents; Antipsychotic tests; Anxiolytic tests; Electroencephalogram; Glycine transporter 1 inhibitors; Negative symptoms of schizophrenia; NFPS; Org 24461; 3H Glycine efflux; 3H Glycine uptake

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALX 5407; APOMORPHINE; BETA ADRENERGIC RECEPTOR; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLYCINE; GLYCINE DERIVATIVE; HALOPERIDOL; N METHYL N [(4 TRIFLUOROMETHYL)PHENOXY] 3 PHENYLPROPYLGLYCINE; N [3 (4' FLUOROPHENYL) 3 (4' PHENYLPHENOXY)PROPYL]SARCOSINE; ORG 24461; PHENCYCLIDINE; RISPERIDONE; SARCOSINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANXIETY; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; BRAIN SLICE; BRAIN SYNAPTOSOME; CATALEPSY; CLIMBING; CONFLICT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; HIPPOCAMPUS; HYPERACTIVITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIGHT DARK CYCLE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

EID: 0037343294     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)01078-X     Document Type: Article

References (93)

1. Adams S.G., Kuhar J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16:1993;73-93.
2. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Rev. 31:2000;302-312.
3. Amara R.H., Sato K., Shimada S., Tohyama M., Puschel A.W., Betz H. Gene structure and glial expression of the glycine transporter GLYT1 in embryonic and adult rodents. J. Neurosci. 15:1995;2524-2532.
4. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-D-aspartate. Br. J. Pharmacol. 79:1983;565-575.
5. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur. J. Pharmacol. 283:1995;55-62.
6. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? Neuropsychopharmacology. 18:1998;63-101.
7. Atkinson B.N., De Vivi M., Lechner S.M., Lowalski L., Zeng Y., Klitenck M.A. Characterization of ALX-5407, a GLYT1-selective glycine reuptake inhibitor. Soc. Neurosci. 2000;1653. [Abstr. 619.9].
8. Aubrey K.R., Vanderberg R.J. N[3-(4′-Fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. 134:2001;1429-1436.
9. Balla A., Koneru B., Smiley J., Sershen H., Javitt D.C. Continuous phencyclidine treatment induced schizophrenia-like hyperactivity of striatal dopamine release. Neuropsychopharmacology. 25:2001;157-164.
10. Berger A.J., Dieudonne S., Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 80:1998;3336-3340.
11. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15730-15734.
12. Bilkei-Gorzo A., Gyertyan I., Levay G. mCPP-induced anxiety in the light-dark box in rats - a new method for screening anxiolytic activity. Psychopharmacology. 136:1998;291-298.
13. 3H]SCH-23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35:1984;1885-1893.
14. Borowsky B., Hoffman B.J. Analysis of a gene encoding two glycine transporter variants reveals alternative promoter usage and a novel gene structure. J. Biol. Chem. 273:1998;29077-29085.
15. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
16. Brown A., Carlyle I., Clark J., Hamilton W., Gibson S., McGarry G.et al. Discovery and SAR of Org 24598 - a selective glycine uptake inhibitor. Bioorg. Med. Chem. Lett. 11:2001;2007-2009.
17. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropharmacology. 15:1995;177-213.
18. Bujas-Bobanovic M., Bird D.C., Robertson H.A., Dursun S.M. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br. J. Pharmacol. 130:2000;1005-1012.
19. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
20. Chojnacka-Wojcik E., Tatarczynska E., Deren-Wesolek A. Effect of glycine on antidepressant- and anxiolytic-like action of L-aminocyclopropanecarboxylic acid (ACPC) in rats. Pol. J. Pharmacol. 48:1996;627-629.
21. Corssen G., Domino E.F. Further pharmacologic studies and first clinical experience with the phencyclidine derivative C1-581. Anesth. Analg. 45:1966;29-40.
22. Cosgrove J., Newell T.G. Recovery of neuropsychological functions during reduction in use of phencyclidine. J. Clin. Psychol. 47:1991;159-169.
23. Costall B., Naylor R.J. Mesolimbic and extrapyramidal sites for the mediation of stereotyped behavior patterns and hyperactivity by amphetamine and apomorphine in the rat. Adv. Behav. Biol. 21:1977;47-76.
24. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Tomkins D.M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol. Biochem. Behav. 32:1989;777-785.
25. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry. 3:1996;241-253.
26. Creese I., Stewart K., Snyder H.S. Species variations in dopamine receptor binding. Eur. J. Pharmacol. 60:1979;55-66.
27. Danysz W., Parson C.G. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50:1998;597-664.
28. 3H]Glycine uptake in rat hippocampus: kinetic analysis and autoradiographic localization. Brain Res. 572:1992;154-163.
29. 3H]glycine uptake in rat forebrain: cellular localization in the hippocampus. Neurosci. Lett. 161:1993;4-8.
30. Foster A.C., Kemp J.A. Glycine maintains excitement. Nature. 338:1989;377-378.
31. Foster A.C., Wong E.H.F. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br. J. Pharmacol. 91:1987;403-409.
32. Ge J., Hamilton W., Collie I., Shahid M., Hill D., Mason A.et al. Effect of ORG 24598 on glycine levels in brain regions of freely moving rats. Soc. Neurosci. 1999;165. [Abst. 68.2].
33. Gray E.G., Whittaker V.P. The isolation of nerve endings from brain: an electron microscopic study of cell fragments derived by homogenization and centrifugation. J. Anat. 96:1962;79-88.
34. 3H-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 55:1979;323-326.
35. Grotta J., Clark W., Coull B., Pettigrew C., Mackay B., Goldstein L.B.et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a Phase IIa randomized trial. Stroke. 26:1995;602-605.
36. Gunasekara N.S., Spencer C.M., Keating G.M. Ziprasidone. A review of its use in schizophrenia and schizoaffective disorder. Drugs. 62:2002;1217-1251.
37. Harsing L.G. Jr., Sershen H., Lajtha A. Dopamine efflux from striatum after chronic nicotine: evidence for autoreceptor desensitization. J. Neurochem. 59:1992;48-54.
38. 3H]glycine release in the rat brain. Neurochem. Res. 26:2001;915-923.
39. Harsing LG Jr, Gacsalyi I, Levay G, Schmidt E, Matyus P, Sebban C, Spedding M. Some pharmacological effects of glycine transporter (GlyT1) inhibitors. Winter Conference of Brain Research; 2002.
40. Herdon H.J., Godfrey F.M., Brown A.M., Coulton S., Evans J.R., Cairns W.J. Pharmacological assessment of the role of glycine transporter GlyT-1 in mediating high affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology. 41:2001;88-96.
41. Heresco-Levy U., Silipo G., Javitt D.C. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol. Bull. 32:1996;731-740.
42. Hoffman D.C., Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology. 120:1995;128-133.
43. Javitt D.C., Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake implication for schizophrenia and substance abuse. Psychopharmacology. 129:1997;96-98.
44. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
45. Javitt D.C., Balla A., Sershen H., Lajtha A. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry. 45:1999;668-679.
46. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
47. Kahn R.S., Davis K.L. New developments in dopamine and schizophrenia. Bloom F.E., Kupfer D.J. Psychopharmacology: the fourth generation of progress. 1995;1215-1228 Raven Press, New York.
48. Kane J.M., Freeman H.L. Towards more effective antipsychotic treatment. Br. J. Psychiatry. 165:1994;22-31.
49. B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology. 36:1997;1355-1367.
50. Kim K.M., Kingsmore S.F., Han H., Yang-Feng T.L., Godinot N., Seldin M.F.et al. Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol. Pharmacol. 45:1994;608-617.
51. Kitaichi K., Yamada K., Hasegawa T., Furukawa H., Nabeshima T. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin. J. Pharmacol. 66:1994;181-189.
52. B receptor partial agonist, D-cycloserine, in rats. Pharmacological analysis. Psychopharmacology. 152:2000;224-228.
53. Kristensen J.D., Svensson B., Gordh T. The NMDA-receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain. 51:1992;249-253.
54. Lahti A.C., Weiler M.A., Michaelidis T., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 25:2001;455-467.
55. 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 21:1982;301-314.
56. Lieberman J.A. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br. J. Psychiatry Suppl. 22:1993;7-18.
57. Litchfield J.T., Wilcoxon F. Simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
58. Mallard N.J., Hudson A.L., Nutt D.J. Characterization and autoradiographical localization of nonadrenoceptor idazoxan binding sites in the rat brain. Br. J. Pharmacol. 106:1992;1019-1027.
59. Martin P., Svensson A., Carllson A., Carlsson M.L. MK-801-induced hyperlocomotion: differential effects of MDL 100,907, SDZ PSD 958 and raclopride. Eur. J. Pharmacol. 335:1997;107-116.
60. 2A receptors. Eur. J. Pharmacol. 280:1995;R9-R11.
61. Meltzer H.Y. Atypical antipsychotic drugs. Bloom F.E., Kupfer D.J. Psychopharmacology: the fourth generation of progress. 1995;1277-1286 Raven Press, New York.
62. Millan M.J., Schreiber R., Dekeyne A., Rivet J.M., Bervoets K., Mavridis M.et al. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]- 1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;1356-1373.
63. Millan M.J., Brocco M., Gobert A., Schreiber R., Dekeyne A. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]- 1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 288:1999;1002-1014.
64. Miyasaka M., Domino E.F. Neural mechanisms of ketamine-induced anesthesia. Neuropharmacology. 7:1968;557-573.
65. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group of II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
66. Morpurgo C. Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction. Arch. Int. Pharmacodyn. 137:1962;84-88.
67. Mothet J.-P., Parent A.T., Wolosker H., Brady R.O. Jr., Linden D.J., Ferris C.D.et al. D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4926-4931.
68. Ninan I., Kulkarni S.K. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. Eur. J. Pharmacol. 368:1999;1-7.
69. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11:1998;523-569.
70. Pazos A., Hoyer D., Palacios J.M. The binding of serotonergic ligands to the pocine chorioid plexus: characterization of a new type of serotonin recognition site. Eur. J. Pharmacol. 106:1985;539-546.
71. 1C binding sites in rat frontal cortex. J. Neurochem. 47:1986;529-540.
72. Phillips M., Wang C., Johnson K.M. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J. Pharmacol. Exp. Ther. 296:2001;905-913.
73. Pronce J., Poyatos I., Aragon C., Gimenez C., Zafra F. Characterization of the 5′ region of the rat brain glycine transporter GLYT2 gene: identification of a novel isoform. Neurosci. Lett. 242:1998;25-28.
74. Pullan L.M., Powell R.J. Comparison of binding at strychnine-sensitive (inhibitory glycine receptor) and strychnine-insensitive (N-methyl-D-aspartate receptor) glycine binding sites. Neurosci. Lett. 148:1992;199-201.
75. 3H]-idazoxan. J. Neural Transm. 68:1987;79-95.
76. Reynolds I.J., Miller R.J. Multiple sites for the regulation of the N-methyl-D-aspartate receptor. Mol. Pharmacol. 325:1988;581-584.
77. Sato K., Adams R., Betz H., Schloss P. Modulation of a recombinant glycine transporter (GLYT1b) by activation of protein kinase C. J. Neurochem. 65:1995;1967-1973.
78. Sebban C., Zang Q.X., Tesolin-Decros B., Millan M.J., Spedding M. Changes in EEG spectral power in the prefrontal cortex of conscious rat elicited by drugs interaction with dopaminergic and noradrenergic transmission. Br. J. Pharmacol. 128:1999;1045-1054.
79. 2A receptors. Br. J. Pharmacol. 135:2001;65-78.
80. Smith K.E., Borden A., Hartig P.R., Branchek T., Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron. 8:1992;927-935.
81. Snyder S.H., Kim P.M. D-Amino acids as putative neurotransmitters: focus on D-serine. Neurochem. Res. 25:2000;553-560.
82. Tamminga C.A. Serotonin and schizophrenia. Biol. Psychiatry. 44:1998;1079-1080.
83. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12:1998;21-36.
84. Toth E., Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem. Res. 11:1986;393-400.
85. Toth E., Weiss B., Banay-Schwartz M., Lajtha A. Effect of glycine derivatives on behavioral changes induced by 3-mercaptopropionic acid or phencyclidine in mice. Psychol. Psychiatr. Behav. 11:1986;1-9.
86. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 44:1998;1081-1089.
87. Uhl G.R., Hartig P.R. Transport explosion: update on uptake. Trends Pharmacol. Sci. 13:1992;421-425.
88. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing antianxiety agents. Psychopharmacologia (Berl.). 21:1971;1-7.
89. Wallace R.A., Wallace L., Harrold M., Miller D., Uretsky N.J. Interaction of permanently charged chlorpromazine and dopamine analogs with the striatal D-1 dopaminergic receptor. Biochem. Pharmacol. 38:1989;2019-2025.
90. Wiley L., Compton A.D., Porter J.H. Effects of four antipsychotics on punished responding in rats. Pharmacol. Biochem. Behav. 45:1993;263-267.
91. Winslow I.T., Insel T.R., Trullas R., Skolnick P. Rat pup isolation calls are reduced by functional antagonists of the NMDA receptor complex. Eur. J. Pharmacol. 190:1990;11-21.
92. Zafra F., Aragon C., Oliveras L., Danbolt N.C., Gimenez C., Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells. J. Neurosci. 15:1995;3952-3969.
93. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G., Mack R.J., Wozniak P.J. Controlled dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry. 154:1997;782-791.